Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Outlook’s CEO steps down; Lawrence Kenyon named interim CEO

Outlook Therapeutics (NASDAQ:OTLK) has appointed Lawrence Kenyon, EVP, CFO, and board member, as interim CEO, effective immediately. Russell Trenary has stepped down as the company’s president and CEO. Mr. Kenyon has...

December 4, 2024

Developments

Medicus enters agreement with Swanielle to expand Phase 2 trial in APAC

Medicus Pharma (NASDAQ:MDCX) (TSXV:MDCX) announced a collaborative agreement with Swanielle to explore the expansion of its SKNJCT-003 Phase 2 clinical study for the treatment of basal cell carcinoma in the Asia-Pacific...

December 2, 2024

Developments

FDA accepts Revelation’s IND for Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted its investigational new drug (IND) application for Gemini in chronic kidney disease (CKD). The company notes that the milestone enables the launch...

December 2, 2024

Developments

Elite launches generic hydrocodone and acetaminophen tables for pain management

Elite Pharmaceuticals (OTCQB:ELTP) announced it has launched a generic version of Norco tablets, a combination of hydrocodone bitartrate and acetaminophen for pain management. The generic hydrocodone bitartrate and...

December 2, 2024

Developments

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a definitive co-sales and co-marketing agreement with Siemens Healthineers (XETRA:SHL) pursuant to which the companies will commercialize a new MRI-guided prostate...

December 2, 2024

Developments

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

CervoMed (NASDAQ:CRVO) announced that the FDA has granted orphan drug designation (ODD) to its lead investigational therapy, neflamapimod, for the treatment of frontotemporal dementia (FTD). Following the announcement...

November 28, 2024

Developments

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V: PINK; OTC: PYNKF) highlighted the November 26, 2024 webinar entitled, “Clearer Margins. Greater Confidence. Exploring the Benefits of OTC”, sponsored by the American Society of...

November 27, 2024

Developments

Profound Medical to unveil 3rd TULSA-AI module, ‘UA Alignment Assistant’, at upcoming medical meetings

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it will unveil its third TULSA-AI software module, UA Alignment Assistant at the upcoming 110th Scientific Assembly and Annual Meeting of the Radiological Society...

November 26, 2024

Developments

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

MaaT Pharma (EURONEXT: MAAT) announced that its IASO Phase 1b clinical trial, evaluating the safety and tolerability of multiple doses of MaaT003 in amyotrophic lateral sclerosis (ALS), has met its primary endpoint...

November 26, 2024

Developments

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

IMUNON (NASDAQ: IMNN) announced the results of its end-of-Phase 2 meeting with the FDA supporting investigational interleukin-12 (IL-12) immunotherapy IMNN-001 for the treatment of advanced ovarian cancer into a 500...

November 26, 2024

Markets

Leede Financial starts Nanalysis Scientific at buy; PT C$0.90

Leede Financial launched coverage of Nanalysis Scientific (TSXV: NSCI) (OTCQX: NSCIF) with a “speculative buy” rating and C$0.90 target price. The stock closed at $0.365 on November 22. Nanalysis operates two distinct...

November 25, 2024

Developments

Ikonisys wins contract for Ikoniscope20 robotic microscope in Italy

Ikonisys Group (Euronext Paris:ALIKO) announced that its subsidiary, Hospitex, has been awarded a public tender to supply the innovative Ikoniscope20 robotic microscope to the Department of Pathological Anatomy in...

November 25, 2024

Outlook’s CEO steps down; Lawrence Kenyon named interim CEO

Medicus enters agreement with Swanielle to expand Phase 2 trial in APAC

FDA accepts Revelation’s IND for Gemini in CKD

Elite launches generic hydrocodone and acetaminophen tables for pain management

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

Profound Medical to unveil 3rd TULSA-AI module, ‘UA Alignment Assistant’, at upcoming medical meetings

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

Leede Financial starts Nanalysis Scientific at buy; PT C$0.90

Ikonisys wins contract for Ikoniscope20 robotic microscope in Italy

General

More